Phase I, double-blind, randomised, placebo-controlled, single-ascending dose trial of ITI 214 in healthy volunteers.
Latest Information Update: 21 Feb 2013
At a glance
- Drugs Lenrispodun (Primary)
- Indications Cognition disorders; Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Intra-Cellular Therapies
- 21 Feb 2013 New trial record